In Vivo CRO 시장 : 동물 모델별, 서비스별, 약물 유형별, 치료 영역별, 최종 용도별, 세계 예측(2024-2032년)

In Vivo CRO Market size is estimated to register 7.8% CAGR between 2024-2032, driven by the increasing demand for advanced preclinical testing and research services. As pharmaceutical and biotechnology companies are striving to accelerate drug development timelines and reduce costs, they are increasingly outsourcing their in vivo studies to specialized CROs. For instance, in March 2023, as part of NVIDIA AI Foundations, the new BioNeMo Cloud Service accelerated life sciences research, drug discovery, and protein engineering. These organizations offer expertise in conducting complex animal studies while ensuring compliance with regulatory standards and providing high-quality data.

With the advent of new technologies, such as CRISPR and advanced imaging techniques, in vivo studies have become more sophisticated and capable of providing deeper insights into disease mechanisms and treatment effects. This has led to an increased reliance on CROs that possess the necessary infrastructure and expertise to conduct these cutting-edge studies. The growing trend of precision medicine, which requires extensive in vivo research to develop targeted therapies, is also boosting the market growth.

The industry is classified into animal model, service, drug type, therapeutic area, end use, and region.

Based on service, the in vivo CRO market size from the toxicity studies segment is anticipated to witness substantial growth through 2032. Regulatory authorities require comprehensive toxicity data before approving any new pharmaceutical products, making toxicity studies an essential part of the drug development process. In vivo CROs offer specialized expertise and advanced facilities to conduct these complex studies while adhering to stringent regulatory guidelines and providing reliable data.

In vivo CRO market from the clinical pharmacology segment is anticipated to observe a significant CAGR between 2024 - 2032. This is due to its cruciality in understanding the pharmacokinetics and pharmacodynamics of new drug candidates, which are crucial for determining their safety, efficacy, and optimal dosing regimens. In vivo CROs specializing in clinical pharmacology offer advanced capabilities to conduct thorough and precise studies, including absorption, distribution, metabolism, and excretion (ADME) analysis.

Asia Pacific in vivo CRO industry will record impressive growth over 2024-2032 attributed to the expanding pharmaceutical and biotechnology sectors, bolstered by significant investments in R&D activities. The increasing prevalence of chronic diseases is accelerating the need for new therapeutic solutions, thereby driving the demand for in vivo CRO services. The presence of advanced infrastructure and the adoption of innovative technologies will further boost the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing outsourcing by pharmaceutical and biotechnology companies
    • 3.2.1.2 Stringent regulatory landscape for drug approvals
    • 3.2.1.3 Focus on specialized services by CRO's
    • 3.2.1.4 Rising demand for personalized medicine
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Intellectual property rights issues
    • 3.2.2.2 Stringent regulatory policies for animal model use
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Model, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Rodent-based
  • 5.2.1 Rat models
  • 5.2.2 Mice models
  • 5.2.3 Other rodent models
• 5.3 Non-rodent-based

Chapter 6 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Bioanalysis & DMPK studies
• 6.3 Toxicity studies
  • 6.3.1 GLP toxicology studies
  • 6.3.2 Non-GLP toxicology studies
• 6.4 Other services

Chapter 7 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Small-molecule drugs
• 7.3 Large-molecule drugs
  • 7.3.1 Cell & gene therapy
  • 7.3.2 RNA therapy
  • 7.3.3 Other large molecule drugs

Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Clinical pharmacology
• 8.4 Cardiology
• 8.5 Infectious diseases
• 8.6 Neurology
• 8.7 Gastroenterology & hepatology
• 8.8 Metabolic & endocrine
• 8.9 Ophthalmology
• 8.10 Autoimmune / inflammatory conditions
• 8.11 Other therapeutic areas

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 Pharmaceutical & bio pharmaceutical companies
• 9.3 Medical device companies
• 9.4 Academic & research institutes

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Biocytogen
• 11.2 Charles River Laboratories International Inc.
• 11.3 Crown Bioscience
• 11.4 Evotec
• 11.5 GemPharmatech
• 11.6 IQVIA Inc.
• 11.7 Icon Plc
• 11.8 Labcorp Drug Development
• 11.9 Parexel International Corporation
• 11.10 PsychoGenics Inc.
• 11.11 Taconic Biosciences, Inc.